https://finance.yahoo.com/quote/MBRX?p=MBRXhttps://finance.yahoo.com/quote/MBRX?p=MBRXMoleculin Signs Agreement with MD Anderson Cancer Center for Leukemia Drug, Annamycin
MarketwiredJuly 18, 2017
Comment
HOUSTON, TX--(Marketwired - July 18, 2017) - Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has signed a new technology license agreement with MD Anderson Cancer Center based on new patent applications it intends to file relating to its drug Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML).
"In anticipation of beginning our planned clinical trials for Annamycin," commented Walter Klemp, CEO of Moleculin, "one of our priorities has been to ensure the best possible protection for our intellectual property. Some key patent applications had yet to be filed and signing a new license agreement with MD Anderson clears the way for those patents."
Mr. Klemp continued: "we have benefitted greatly from our collaboration with MD Anderson, and this license helps ensure that collaboration continues."
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a preclinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two preclinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system. The other portfolio targets the metabolism of tumors.
For more information about the Company, please visit
http://www.moleculin.com.
$MBRX:
Institutional holders:
Moleculin Biotech Inc, Inst Holders, 2Q 2017 (MBRX)
4:15 am ET July 20, 2017 (Dow Jones) Print
The following table shows the largest shareholders in MOLECULIN BIOTECH INC COM (MBRX) for the quarter ended June 30, 2017, listed by holding size. The list represents up to 50 of the largest holders in the company.
Institution Shares Shares % Last
Held Changed Held Report
The Vanguard Group Inc. 264,160 246,202 1.488 03/31
KCG Americas LLC 233,994 233,994 1.318 03/31
Sabby Capital LLC 100,000 100,000 0.563 03/31
Sterling Capital Management LL 40,000 20,000 0.225 03/31
Bank of America NA (Private B 25,000 0 0.141 03/31
Two Sigma Securities LLC 24,160 24,160 0.136 03/31
BlackRock Fund Advisors 17,868 0 0.101 03/31
Goldman Sachs & Co. LLC (Priva 17,509 17,509 0.099 03/31
Citadel Advisors LLC 17,304 17,304 0.097 03/31
Northern Trust Investments In 11,155 11,155 0.063 03/31
Morgan Stanley & Co. LLC 10,096 10,096 0.057 03/31
Wedbush Securities Inc. (Inve 10,000 10,000 0.056 03/31
UBS Securities LLC 4,537 2,415 0.026 03/31
Tower Research Capital LLC 3,100 2,900 0.017 03/31
Acrospire Investment Managemen 2,472 2,472 0.014 03/31
UBS Financial Services Inc. 2,000 2,000 0.011 03/31
Advocacy Wealth Management LLC 1,000 0 0.006 03/31
Morgan Stanley Smith Barney LL 700 0 0.004 03/31
NEXT Financial Group Inc. 500 500 0.003 06/30
WFG Advisors LP 400 0 0.002 03/31
Citigroup Global Markets Inc. 0 (7,500) 0.000 03/31
Moleculin Biotech, Inc. (NASDAQ: MBRX), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today announced it has selected Bioscience SA ('Bioscience'), a Polish contract research organization ('CRO') to begin identifying and preparing clinical testing sites in Poland for Annamycin, its drug candidate for the treatment of relapsed or refractory acute myeloid leukemia (AML). The Company announced on June 15th, an expansion of its agreement with Theradex Systems, Inc. to include oversight of clinical trial activity in Poland and the appointment of a Lead European Principal Investigator on July 6, 2017. Read this and more news for Moleculin Biotech at:
http://www.marketnewsupdates.com/news/mbrx.html.
"Engaging Bioscience gives us experienced boots on the ground in Poland," commented Walter Klemp, CEO of Moleculin, "which we believe is critical, not only for ensuring tight coordination between the US and Polish sites in our upcoming Annamycin clinical trial (which would commence only if our IND for Annamycin is permitted), but also to ensure we have the full benefit of local knowledge regarding site performance and regulatory compliance."
Mr. Klemp continued, "one of the biggest challenges for most clinical trials is recruiting the right patients on a timely basis. We believe adding Polish sites to our planned trial introduces a significant population of qualified patients, and selecting Bioscience helps ensure we reach those patients effectively and efficiently."
This looks very good.
The price doubled in a month, a nice gradual increase.
Today it went up 5%.
I've been looking for something lately to add that's solid, this may be the one.
Good find CD.
This looks very good.
The price doubled in a month, a nice gradual increase.
Today it went up 5%.
I've been looking for something lately to add that's solid, this may be the one.
Good find CD.
it is up another 13 cents after hours.
I think tomorrow it crosses over to $3 and more for good.
we will just have to see how it plays out.
you know all these stocks entail risk.
Biotech Sector Rises on Accelerated Anti-cancer Drug Candidate Developments and Clinical Trial Progress
8:30 am ET August 16, 2017
MarketNewsUpdates.com News Commentary
This month's latest FDA Approval advancements, anti-cancer drug candidate developments and Clinical studies momentum across the biotech and pharma sector continues to accelerate as headlines surrounding the active biotechnology industry advances forward resulting in new levels in the markets. The iShares Nasdaq Biotechnology Index has realized a healthy gain of around 15% so far this year from leaders in the industry including: Moleculin Biotech, Inc. (NASDAQ: MBRX), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Endo International plc (NASDAQ: ENDP), Gilead Sciences Inc. (NASDAQ: GILD) and Microbot Medical Inc. (NASDAQ: MBOT)
Moleculin Biotech, Inc. (NASDAQ: MBRX), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today announced it has acquired WP1122 active drug compound it plans to study for the treatment of brain tumors. Read this and more news for Moleculin Biotech at http://www.marketnewsupdates.com/news/mbrx.html
Walter Klemp, CEO of Moleculin commented: "There has been a lot of excitement recently surrounding the WP1122 technology and its potential to become a new approach for treating brain tumors. We are pleased that we have now secured exclusive access to a significant quantity of GMP synthesized WP1122 drug substance from our sublicense partner in Poland."
"Access to this product allows us to accelerate pre-clinical toxicology and analytical testing of WP1122," Mr. Klemp continued, "which enables preparation of an Investigational New Drug application so we can begin proof of concept clinical trials. Research at MD Anderson using live human brain tumors transplanted into mice has shown that WP1122 has the potential to outperform the current standard of care treatment for glioblastoma, one of the most pervasive forms of brain tumors. We are eager to get this drug into human testing to determine if we have something that could make a real difference for patients."
In other biotech developments and market performance of note:
Teva Pharmaceutical Industries Limited (NYSE: TEVA) came to a close up 4.72% on Tuesday at $17.97 trading over 22.6 million shares by the market close and was down very slightly in afterhours trading. The company recently announced that the U.S. Food and Drug Administration (FDA) has approved QVAR(R) RediHaler(TM) (beclomethasone dipropionate HFA) inhalation aerosol, a breath-actuated inhaler for the maintenance treatment of asthma as a prophylactic therapy in patients four years of age and older. QVAR(R) RediHaler(TM) is not indicated for the relief of acute bronchospasm. The product is expected to become commercially available in both 40mcg and 80mcg strengths to patients by prescription during the first quarter of 2018.
Endo International plc (NASDAQ: ENDP) closed up over 6% on Tuesday at $8.14 with over 9.9 million shares traded on the day. The company recently announced second-quarter 2017 financial results. Total revenues decreased by 5 percent to $876 million in second-quarter 2017 compared to the same period in 2016 primarily due to generic competition adversely impacting the Branded Established Products portfolio. GAAP net loss from continuing operations in second-quarter 2017 was $696 million compared to GAAP net income from continuing operations of $390 million during the same period in 2016. This decrease was primarily attributable to charges associated with the Company's manufacturing network restructuring; after-tax impairment charges associated with market and competitive factors impacting certain products' revenues, the pending Somar divestiture and the market removal of OPANA(R) ER; and second-quarter 2016 recognition of certain net tax benefits. GAAP net loss per share from continuing operations for the second-quarter 2017 was $3.12, compared to diluted GAAP EPS from continuing operations of $1.75 in second-quarter 2016. Read more here: https://finance.yahoo.com/news/endo-reports-second-quarter-2017-103000822.html
Gilead Sciences Inc. (NASDAQ: GILD) closed up slightly on Tuesday with over 5.1 million shares traded by the market close. The company recently announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company's New Drug Application (NDA) for an investigational, fixed-dose combination of bictegravir (50mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF), a dual-NRTI backbone, for the treatment of HIV-1 infection. Gilead filed the NDA for BIC/FTC/TAF with a Priority Review voucher on June 12, 2017, and FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of February 12, 2018.
Microbot Medical Inc. (NASDAQ: MBOT) closed up over 12% on Tuesday with over 1.3 million shares traded by the market close. The company recently announced financial and operational results for the quarter and six months ended June 30, 2017, as well as provided an update on progress towards key strategic initiatives. "As major healthcare companies are seeking to establish capabilities in the medical robotic space, our team is leveraging Microbot's already existing and unique core capabilities and is making meaningful progress with our transformational technological robotic platforms," commented Harel Gadot, CEO, President and Chairman. Read more here: https://finance.yahoo.com/news/microbot-medical-inc-reports-second-200100412.html